Hope for psoriasis sufferers
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.A dramatic advance in the treatment of psoriasis, the debilitating skin condition which affects more than one million people in the UK, was announced by scientists yesterday.
Two trials of a new biological agent, ustekinumab, in almost 2,000 patients with moderate to severe forms of the disease have shown it was highly effective in controlling the painful condition, had few side-effects and was more convenient to take than existing therapies.
More than two-thirds of those treated with the drug, given in two injections a month apart and then at three-month intervals, had better than 75 per cent improvement in the state of their skin. Treatment continued, and the improvement was maintained, for up to 18 months. The results of the trials are published in The Lancet.
One lead investigator, Craig Leonardi, who is associate clinical professor of dermatology at the University of St Louis, Missouri, said: "These were highly significant impressive clinical results and some of the happiest patients I have had the pleasure of treating."
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments